


AMENDMENTS TO THE CLAIMS


This listing of the claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Currently Amended) A compound having formula (I):



I

or a pharmaceutically acceptable salt thereof, wherein X is



R^1 is halogen, lower alkyl or lower cycloalkyl;

R^2 is attached to any available carbon atom of the phenyl ring A and at each occurrence is independently selected from the group consisting of alkyl, lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, OMe, CN and NMe₂;

n is 0 or 1;

Y is $-L-R^3$;

R^3 is hydrogen, alkyl, $-OR^4$, substituted alkyl, cycloalkyl, $-CR^4$ cycloalkyl, a saturated 4 to 7 membered mono cyclic heterocyclyl or a substituted saturated 4 to 7 membered mono cyclic heterocyclyl;

L is $-C(=O)NH-$, $-NH(C=O)-$;

V is $-M-R^{10}$ or R^{14} ;

M is $-C(=O)NR^4-$, $-NR^4(C=O)-$, $-NR^4(C=O)NR^4-$, $-NR^4SO_2-$, or $-C(=O)-$;

R^{14} is aryl or heteroaryl optionally substituted with up to three R^{12} ;

R^4 is each selected from hydrogen, lower alkyl and lower cycloalkyl;

~~R⁶ is attached to any available carbon atom of the phenyl ring B and at each occurrence is independently hydrogen, alkyl, lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, OMe, CN, NH₂, or -NMe₂;~~

~~R¹⁰ is alkyl, substituted alkyl, aryl, or -(CH₂)_t-D-(CH₂)_e-R¹³;~~

~~t is selected from 0, 1, 2 and 3; e is selected from 0, 1, 2 and 3;~~


~~D is selected from a bond, an optionally substituted heterocyclyl, an optionally substituted aryl, -O-, -S-, -(C=O)-, -NR⁴(C=O)-, -(C=O)NR⁴-, -S(O)-, SO₂NR⁴-, SO₂-, and -NR⁴-;~~

~~R¹² is selected from R¹⁰, NO₂, CN, lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, OMe, CN, NMe₂, S(=O)alkyl, S(=O)aryl, NHSO₂aryl, R⁴, NHSO₂alkyl, CO₂R⁴, CONH₂, SO₃H, S(O)alkyl, S(O)aryl, SO₂NHR⁴, and NHC(=O)NHR⁴; and~~

R¹³ is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heteroaryl ring and an optionally substituted fused bicyclic ring.


2. (Cancelled)

3. (Previously Presented) The compound of claim 1 having formula (III):



4. (Cancelled)

5. (Previously Presented) The compound of claim 1 having formula (V):



6-11. (Cancelled)

12. (Previously Presented) The compound of claim 1, wherein R⁶ is lower alkyl or hydrogen.

13-19. (Cancelled)

20. (Previously Presented) The compound of claim 1, wherein M is –
C(=O)NR⁴–.
21. (Previously Presented) The compound of claim 1, wherein M is –
C(=O)NH–.
22. (Cancelled)
23. (Currently Amended) The compound of claim 1, wherein R¹⁰ is 4-
methoxybenzyl.
- 24-28. (Cancelled)
29. (Previously Presented) The compound of claim 1, wherein R¹ is lower alkyl.
- 30-33. (Cancelled)
34. (Previously Presented) The compound of claim 1, wherein R³ is lower
alkyl or lower cycloalkyl.
35. (Previously Presented) The compound of claim 1, wherein R³ is lower
cycloalkyl.
36. (Previously Presented) The compound of claim 1, wherein R³ is
cyclopropyl.
37. (Previously Presented) The compound of claim 1:
N-(4-Methoxybenzyl)-2-[(5-cyclopropylaminocarbonyl)-2-methylphenyl]-4-aminopyrimidine-5-
carboxamide.
- 38-53. (Cancelled)
54. (Previously Presented) A pharmaceutical composition, comprising a compound of
claim 1 and a pharmaceutically acceptable carrier.
- 55-61. (Cancelled)